Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In contrast to TAC, antagonizing the function of CTGF had no effect on LV dysfunction or LV hypertrophy in mice subjected to 4-week angiotensin II infusion.
|
24688123 |
2014 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The potential role of nitric oxide in the hypertrophic growth of the left ventricle.
|
10805403 |
2000 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
The potential role of nitric oxide in the hypertrophic growth of the left ventricle.
|
10805403 |
2000 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was explore the relationship between plasma concentration of angiotensin II (Ang II), Adrenomedulin (ADM) and adrenotensin (ADT) in patients with hypertension and LVH.
|
31217886 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, vasodilators and diuretics, which stimulate adrenoceptor activity and increase angiotensin II levels, were found to be less effective in reversing LV hypertrophy.
|
1380616 |
1992 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Five genetic polymorphisms of the RAAS (ACE, AGTR1, AGT, CMA, CYP11B2) were analyzed in all patients and the results of genetic analysis were correlated to severity of AS and LVH to determine the importance of the polymorphisms for LVH.
|
11275936 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure.
|
14644620 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.
|
12640257 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight chronically instrumented pigs receiving continuous angiotensin II infusion during 28days to induce chronic hypertension and LV hypertrophy.
|
29196088 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes.
|
10440164 |
1999 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The angiotensin II subtype 1 (AT1) receptor antagonist valsartan suppressed the elevated blood pressure completely and left ventricular hypertrophy incompletely, but did not affect the other phenotypes.
|
14620933 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen (AGT), the precursor of angiotensin II and a rate limiting factor in the renin-angiotensin system, is implicated in left ventricular hypertrophy, as angiotensin II is a potent stimulator of cardiac growth.
|
16280278 |
2005 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the induction of human cardiac fibroblasts (HCF) and human umbilical vein endothelial cells (HUVEC) with the LVH mediator angiotensin II enabled us to investigate uremic LVH progression in vitro.
|
19094982 |
2009 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs.
|
20837116 |
2010 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequency of IT genotype of ATG gene in patients with LVH was significantly (P<0.01) greater than that in normal controls or marginally (P=0.1) higher than that in patients without LVH.
|
10646957 |
2000 |
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACE is responsible for the generation of angiotensin II, which is implicated in the development of left ventricular hypertrophy, an independent risk factor for morbidity and mortality in hypertension.
|
7820539 |
1994 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
1.The relationship between the angiotensinogen (AGT) T174M, angiotensin converting enzyme (ACE) insertion/deletion (I/D) and the angiotensin II type 1 receptor (AT1) genetic markers and left ventricular hypertrophy was examined in normal subjects and those with aortic stenosis.2.
|
8800593 |
1996 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, neither ID ACE-gene polymorphism nor ATI-receptor gene and angiotensinogen gene polymorphism was associated with LVH.
|
11688760 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We challenged C57BL/6 adult male mice with an infusion of AngII (osmotic pumps; 2 mg/kg.day) to induce LVH.
|
30267750 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen M235T and T174M polymorphisms have individually been associated with elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy.
|
17145981 |
2007 |